TerminatedPhase 3NCT02562443
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Studying Myelodysplastic neoplasm with increased blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Traws Pharma, Inc.
- Principal Investigator
- Steven M. Fruchtman, MDTraws Pharma, Inc.
- Intervention
- rigosertib(drug)
- Enrollment
- 372 enrolled
- Eligibility
- 18-81 years · All sexes
- Timeline
- 2015 – 2021
Study locations (30)
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCLA Medical Center, Los Angeles, California, United States
- Cancer Specialists of North Florida, Fleming Island, Florida, United States
- UF Health Shands Cancer Hospital, Gainesville, Florida, United States
- Mid Florida Hematology and Oncology Centers, Orange City, Florida, United States
- Advanced Research Institute, Inc, St. Petersburg, Florida, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Illinois Cancer Center, Chicago, Illinois, United States
- Loyola University Chicago at Loyola University Medical Center, Maywood, Illinois, United States
- Indiana University Health Hospital, Indianapolis, Indiana, United States
- The University of Kansas Cancer Center, Westwood, Kansas, United States
- Tulane Medical Center, New Orleans, Louisiana, United States
- University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02562443 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with increased blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06616636A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)M.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06138587Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04994808Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT04741945Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDSKirsten Grønbæk
- RECRUITINGPHASE1NCT04275518A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.Ascentage Pharma Group Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT03974217Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03682536A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveCelgene
- RECRUITINGPHASE1, PHASE2NCT03471260Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesM.D. Anderson Cancer Center
See all trials for Myelodysplastic neoplasm with increased blasts →